Warby Parker Inc. (WRBY)
USD 23.71
(-2.39%)
USD 23.71
(-2.39%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -63.19 Million USD | 42.75% |
| 2022 | -110.39 Million USD | 23.48% |
| 2021 | -144.27 Million USD | -158.0% |
| 2020 | -55.91 Million USD | 2.81% |
| 2019 | -57.53 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -6.76 Million USD | -152.41% |
| 2024 Q1 | -2.67 Million USD | 85.93% |
| 2023 Q4 | -19.04 Million USD | -9.38% |
| 2023 Q3 | -17.41 Million USD | -9.34% |
| 2023 Q2 | -15.92 Million USD | -47.29% |
| 2023 Q1 | -10.81 Million USD | 46.61% |
| 2023 FY | -63.19 Million USD | 42.75% |
| 2022 Q3 | -23.84 Million USD | 25.88% |
| 2022 Q2 | -32.16 Million USD | 5.76% |
| 2022 Q1 | -34.13 Million USD | 25.64% |
| 2022 FY | -110.39 Million USD | 23.48% |
| 2022 Q4 | -20.25 Million USD | 15.07% |
| 2021 Q4 | -45.9 Million USD | 49.6% |
| 2021 FY | -144.27 Million USD | -158.0% |
| 2021 Q3 | -91.07 Million USD | -783.6% |
| 2021 Q2 | -10.3 Million USD | -442.31% |
| 2021 Q1 | 3.01 Million USD | 170.02% |
| 2020 Q4 | -4.3 Million USD | 89.67% |
| 2020 Q3 | -41.61 Million USD | -731.66% |
| 2020 Q1 | -5 Million USD | 0.0% |
| 2020 Q2 | -5 Million USD | 0.0% |
| 2020 FY | -55.91 Million USD | 2.81% |
| 2019 FY | -57.53 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alcon Inc. | 974 Million USD | 106.488% |
| AptarGroup, Inc. | 284.48 Million USD | 122.214% |
| Baxter International Inc. | 2.65 Billion USD | 102.379% |
| Becton, Dickinson and Company | 1.72 Billion USD | 103.661% |
| Bausch + Lomb Corporation | -260 Million USD | 75.693% |
| Haemonetics Corporation | 117.55 Million USD | 153.758% |
| Envista Holdings Corp | -100.2 Million USD | 36.929% |
| ResMed Inc. | 1.02 Billion USD | 106.19% |
| Teleflex Incorporated | 356.32 Million USD | 117.736% |
| West Pharmaceutical Services, Inc. | 593.4 Million USD | 110.65% |